title: Cystoid macular edema in anterior chamber lens implantation following posterior capsule rupture.
abstract: By comparing the incidence of cystoid macular edema (CME) in three groups of patients having different surgical procedures, we attempted to assess the role of vitreous loss as a risk factor for CME development. In the first group (n = 470), the surgical procedure was extracapsular cataract extraction followed by implantation of posterior chamber lens (EC-CE + PC-IOL). The second group (n = 42) had extracapsular cataract extraction which was complicated by posterior capsule rupture, and therefore anterior vitrectomy followed by implantation of anterior chamber lens had to be performed (ECCE + anterior vitrectomy + AC-IOL). In the third group (n = 22) the surgery was intracapsular cataract extraction followed by anterior chamber lens implantation (ICCE + AC-IOL). The third group was included in this follow up study to assess the role of AC-IOL as a possible causative factor for development of CME in uncomplicated cases of ICCE and AC-IOL. The difference of incidences of CME in the second and third group would therefore depend mostly on the vitreous loss. The incidence of CME diagnosed by fluorescein angiography in the first, second and third group was 1.5% (7/470), 35.7% (15/42) and 9.0% (2/22), respectively. All patients who developed CME were treated with combination of corticosteroid-antibiotic drops, dexamethasone retrobulbarly (40 mg/day) and peroral indomethacin (25 mg/day/6 weeks). This therapeutic regime resulted in only moderate improvement of visual acuity.
authors: Department of Ophthalmology, General Hospital Sveti Duh Zagreb, Croatia.
authors: G
authors: G
authors: Nikica
authors: H P
authors: HP
authors: Ljerka
authors: P
authors: P
authors: Jelena
authors: K
authors: K
authors: Metez-Soldo
authors: B
authors: B
authors: Mladen
mesh_terms: D000867:Anterior Chamber / Q000601:surgery*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002387:Cataract Extraction / Q000009:adverse effects*; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007903:Lens Capsule, Crystalline / Q000293:injuries*; D007910:Lenses, Intraocular / Q000009:adverse effects*; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology*; D012307:Risk Factors; D012421:Rupture; D014821:Vitrectomy
chemical_list: D000900:Anti-Bacterial Agents; D005938:Glucocorticoids